Cargando…
Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay.
Soluble cytokeratin fragment 19 levels were measured with an enzyme immunoassay method developed by Boehringer Mannheim (Enzymun-Test CYFRA 21-1) in the serum of 185 patients with lung cancer [149 with non-small-cell lung cancer (NSCLC) and 36 with small-cell lung cancer (SCLC)] and 97 patients with...
Autores principales: | Takada, M., Masuda, N., Matsuura, E., Kusunoki, Y., Matui, K., Nakagawa, K., Yana, T., Tuyuguchi, I., Oohata, I., Fukuoka, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033433/ https://www.ncbi.nlm.nih.gov/pubmed/7529525 |
Ejemplares similares
-
Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer
por: Uenishi, T, et al.
Publicado: (2003) -
Clinical Usefulness of CYFRA Assay in Diagnosing Lung Cancer: Measurement of Serum Cytokeratin Fragment
por: Sugama, Yasuo, et al.
Publicado: (1994) -
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2020) -
Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
por: Giovanella, L., et al.
Publicado: (2017) -
Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer
por: Xu, Youtao, et al.
Publicado: (2015)